Navigation Links
Vanda Pharmaceuticals Inc. Proposes Public Offering of Common Stock
Date:8/6/2013

WASHINGTON, Aug. 6, 2013 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA) today announced that it intends to offer and sell shares of its common stock in an underwritten public offering. The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. Vanda also expects to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of common stock offered in the public offering to cover over-allotments, if any. All of the shares in the offering are to be sold by Vanda, with net proceeds to be used for sales and marketing expenditures which may include commercial launch activities for tasimelteon for the treatment of Non-24-Hour Disorder following the receipt of regulatory approval, if any, research and development activities and other general corporate purposes.

Lazard Capital Markets LLC and Piper Jaffray & Co. are acting as the joint book-running managers of the offering.

A shelf registration statement on Form S-3 relating to the public offering of the shares of common stock described above was filed with the Securities and Exchange Commission (SEC) and declared effective by the SEC on February 11, 2011. A preliminary prospectus supplement relating to and describing the terms of the offering will be filed with the SEC and will be available on the SEC's web site at www.sec.gov. When available, copies of the preliminary prospectus supplement relating to these securities may also be obtained from the offices of Lazard Capital Markets LLC at 30 Rockefeller Plaza, 60th Floor, New York, NY, 10020 or via telephone at (800) 542-0970 or the offices of Piper Jaffray & Co., by mail at 800 Nicollet Mall, J12S03, Minneapolis, MN 55402, by telephone at (800) 747-3924 or by e-mail at prospectus@pjc.com.

This press release does not constitute an offer to sell or the solicitation of an offer to buy any of these securities, nor will there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale is not permitted.

About Vanda Pharmaceuticals Inc.

Vanda Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of products for the treatment of central nervous system disorders.  For more information on Vanda, please visit www.vandapharma.com.  

Cautionary Statement Regarding Forward-Looking Statements

This communication includes forward-looking statements regarding events, trends and business prospects, which may affect Vanda's future operating results and financial position. Such statements, including, but not limited to, those regarding statements about Vanda's expectations regarding its fundraising efforts, including the closing of the public offering and the underwriter's exercise of its over-allotment option, involve known and unknown risks that relate to Vanda's future events or future financial performance and the actual results could differ materially from those discussed in this communication. Risks and uncertainties that may cause Vanda's actual results to differ materially from those discussed in this communication can be found in the "Risk Factors" section of Vanda's Form 10-K, Forms 10-Q and its other filings with the Securities and Exchange Commission. Readers are cautioned not to place undue reliance on these forward-looking statements that speak only as of the date hereof, and Vanda assumes no responsibility to update or revise any forward-looking statements contained in this communication to reflect events, trends or circumstances after the date of this communication.

Company Contact:

Jim Kelly
Senior Vice President and Chief Financial Officer
Vanda Pharmaceuticals Inc.
(202) 734-3428
jim.kelly@vandapharma.com

Media Contact:

Laney Landsman
Assistant Vice President
Makovsky
(212) 508-9643
llandsman@makovsky.com


'/>"/>
SOURCE Vanda Pharmaceuticals Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. UPCOMING DEADLINE: Levi & Korsinsky Notifies Investors with Losses on Their Investment in Vanda Pharmaceuticals, Inc. of Class Action Lawsuit and the Deadline of August 24, 2013 to Seek a Lead Plaintiff Position
2. Vanda Pharmaceuticals Reports Second Quarter 2013 Results
3. Vanda Pharmaceuticals to Announce Second Quarter 2013 Financial Results on July 31, 2013
4. Vanda Pharmaceuticals to Participate in Upcoming Investor Conferences
5. Vanda Pharmaceuticals, Inc. Sued by Investor
6. Vanda Presents Data From Phase III Studies that Demonstrate Tasimelteon Restores Daily Cortisol Rhythm In Blind Patients With Non-24-Hour Disorder
7. Vanda Presents Data From Tasimelteon Phase III Studies In Non-24-Hour Disorder
8. Vanda Pharmaceuticals to Present at the Jefferies 2013 Global Healthcare Conference
9. Vanda Announces Submission To FDA Of A New Drug Application For Tasimelteon For The Treatment Of Non-24-Hour Disorder In The Totally Blind
10. Vanda to Present Tasimelteon Non-24 Phase III Data at Two Medical Meetings
11. Vanda Pharmaceuticals Named the 2013 Life Science Firm of the Year by the Tech Council of Maryland
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/16/2017)... N.J. , June 16, 2017 Datascope Corp. is ... by Datascope Corp. for a potential electrical test failure code.     ... PART NUMBER ... CS100 IABP CS300 IABP ... ...
(Date:6/14/2017)... CALABASAS, Calif. , June 14, 2017 ... with the City of Fremont ... chain of the bio-pharma industry in California ... sharing technology, enabling executive networking, and fostering workforce development. ... the development and growth of start-ups, as well as ...
(Date:6/12/2017)... 2017 Kineta, Inc., a biotechnology company focused on ... Vice President of R&D and Head of Virology Kristin Bedard ... for the Northwest and Beyond meeting sponsored by Life ... 2017 from 8:30-10:30 AM PDT at the Agora Conference Center ... Dr. Bedard will be joined by other leaders in infectious ...
Breaking Medicine Technology:
(Date:6/20/2017)... ... June 20, 2017 , ... This year, ... focused on finding product improvements that could reduce the occurrence of unplanned ... they need help breathing or to provide medication. Sometimes, patient movement can cause ...
(Date:6/20/2017)... ... , ... Uniform Advantage (UA), a multi-channel retailer of medical apparel ... tailored looks and athleisure-inspired outfits. UA Flex fabric is breathable, wrinkle resistant and durable ... trendy looks hitting the medical community, UA Flex is for the medical professional who ...
(Date:6/20/2017)... ... June 20, 2017 , ... John D'Eri, CEO of Rising ... in Adult Autism Award during the Autism Society of America 's 49th ... The Daniel Jordan Fiddle Foundation (DJFF) was founded in 2002 as the nation's ...
(Date:6/20/2017)... ... June 20, 2017 , ... ... radio program, The Sharon Kleyne Hour Power of Water, Global Climate Change and ... to the world’s water crisis and how it affects the human eyes. ...
(Date:6/20/2017)... ... June 20, 2017 , ... As part of an effort ... Professional Benefit Administrators (SPBA) has provided input to the U.S. Senate on health care ... (R - KY), Charles E. Schumer (D - NY) and all other Senate members. ...
Breaking Medicine News(10 mins):